pyrroles has been researched along with Endometrial Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blattler, C; Castonguay, V; Fleming, G; Hirte, H; Ivy, PS; Lheureux, S; Mackay, HJ; Morgan, R; Oza, AM; Wang, L; Welch, S | 1 |
| Bruchim, I; Flescher, E; Reiss, A; Sarfstein, R; Werner, H | 1 |
| Attias-Geva, Z; Bentov, I; Bruchim, I; Fishman, A; Werner, H | 1 |
| Bergadà, L; Dolcet, X; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Sorolla, A; Valls, J; Yeramian, A | 1 |
| Nagy, A; Schally, AV | 1 |
| Baker, B; Engel, JB; Halmos, G; Keller, G; Nagy, A; Schally, AV | 1 |
1 review(s) available for pyrroles and Endometrial Neoplasms
| Article | Year |
|---|---|
Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Endometrial Neoplasms; Epithelial Cells; Female; Gonadotropin-Releasing Hormone; Humans; Male; Ovarian Neoplasms; Prostatic Neoplasms; Pyrroles; Receptors, LHRH | 2005 |
1 trial(s) available for pyrroles and Endometrial Neoplasms
| Article | Year |
|---|---|
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; California; Carcinosarcoma; Chicago; Endometrial Neoplasms; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ontario; Pyrroles; Sunitinib | 2014 |
4 other study(ies) available for pyrroles and Endometrial Neoplasms
| Article | Year |
|---|---|
IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer.
Topics: Acetates; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Dose-Response Relationship, Drug; Endometrial Neoplasms; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Oxylipins; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Time Factors | 2014 |
Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines.
Topics: Apoptosis; Carcinoma, Endometrioid; Carcinoma, Papillary; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction | 2011 |
Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Endometrium; Female; Humans; Indoles; NF-kappa B; Pyrazines; Pyrroles; Sunitinib | 2012 |
Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
Topics: Aged; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Doxorubicin; Endometrial Neoplasms; Female; Humans; Mice; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Pyrroles; Receptors, Somatostatin; RNA, Messenger; Somatostatin; Transplantation, Heterologous | 2005 |